Figures
Citation: Moesker FM, Muskiet FD, Koeijers JJ, Fraaij PLA, Gerstenbluth I, van Gorp ECM, et al. (2013) Fatal Dengue in Patients with Sickle Cell Disease or Sickle Cell Anemia in Curaçao: Two Case Reports. PLoS Negl Trop Dis 7(8): e2203. https://doi.org/10.1371/journal.pntd.0002203
Editor: Scott B. Halstead, Pediatric Dengue Vaccine Initiative, United States of America
Published: August 8, 2013
Copyright: © 2013 Moesker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was funded by the Erasmus MC Rotterdam and by the Dutch government (project number FES0908). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: We have read the journal's policy and have the following conflicts: FMM's, PLAF's, and ADMEO's scientific work is supported by the Virgo consortium, funded by the Dutch government (project number FES0908). In addition ADMEO has share certificates in ViroClinics Biosciences B.V. The majority of the shares in ViroClinics Biosciences B.V. (>75%) are owned by Erasmus MC through its Erasmus MC Holding B.V. To avoid any possible conflict of interest and to safeguard its employees against the possibility of unethical decisions, the Erasmus MC does not allow any of its employees to hold shares in person in any companies that are (partly) owned by Erasmus MC. As a result thereof, any shares provided by such companies to any Erasmus MC employees are held by a Foundation Administration Office. The board of this foundation is appointed by Erasmus MC. The employees receive share certificates of their shares. Apart form those described above the authors have declared that no competing interests exist.
Presentation of Cases
Case 1
A ten-year-old girl with sickle cell disease (SCD) (combined heterozygosity for the abnormal hemoglobin S and abnormal HbC; HbSC) presented to our clinic with a history of four days fever, malaise, and a generalized tonic-clonic convulsion. At presentation she was alert, nauseous, and complained of headache and retro-orbital pain. Temperature was 38.0°C, heart rate (HR) 135/min, blood pressure (BP) 94/62 mmHg, respiratory rate (RR) 20/min; minor hepatosplenomegaly and upper-quadrant abdominal tenderness were present. No further abnormalities were reported on physical examination. Initial lab results revealed a moderate increase of CRP, anemia, thrombocytopenia, prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT), increased liver enzymes, and decreased albumin and hematocrit (Ht) (Table S1). On day two, during defervescence she became hypotensive and was treated with fluid resuscitation and inotropic agents. Blood products were transfused to correct anemia and thrombocytopenia. Hemolysis and acute hemorrhage with gastrointestinal, vaginal, and later on venipuncture sites bleeding developed. Splenic sequestration was also considered as the cause of anemia, but could not be confirmed with abdominal ultrasound. Pleural effusion, gallbladder wall thickening, and ascites were seen. On day three, she lost vision. A brain CT scan revealed no abnormalities. Lumbar puncture was deferred and antibiotic treatment was adjusted to cover possible meningitis. Hereafter she developed acute respiratory distress syndrome (ARDS) requiring mechanical ventilation. Dengue serology was positive for IgM (titer: 3.26) and IgG (3.26) (Focus Diagnostics), and RT-PCR showed dengue virus serotype 2 (DENV-2). Her clinical situation deteriorated with an increased hemorrhagic tendency, and blood, clotting products, and clotting factors were administered. In time multiorgan dysfunction syndrome (MODS) developed. Blood cultures remained negative for bacteria, but antibiotics were administered anyway. Candida was cultured and antifungals were initiated. Despite intensive treatment the patient did not recover, disseminated intravascular coagulation (DIC) progressed and kidney function did not return. Consequently further treatment was discontinued and the patient died, 28 days after admission.
Case 2
A 19-year-old female presented to our clinic with fever, headache, retro-orbital pain, and muscle ache for two days. In addition hematemesis and epistaxis started on the day of admission. Her medical history revealed sickle cell anemia (SCA) (homozygosity for abnormal HbS; HbSS). On examination she was alert, with a temperature of 37°C, BP 120/80 mmHg, HR 100/min, and RR 15–20/min. She had right upper-quadrant abdominal tenderness. No other abnormalities on physical examination were found. Initial lab results revealed moderate increase of CRP, anemia, thrombocytopenia, and increased liver enzymes. NS1-antigen tested positive and dengue serology was negative for IgM (0.41) and positive for IgG (5.71), and RT-PCR showed DENV-2. Shortly after admittance she became hypotensive, with distension of her abdomen. Intravenous fluid resuscitation was started and further intervention was implemented on the basis of the monitoring of hematocrit, urine output, and blood glucose. Profuse abdominal bleeding was suspected, with marked decrease of Hb, low platelets, severe disrupted coagulation parameters, and intra- and retro-abdominal free fluid with fibrin strands on ultrasound. Moreover extensive capillary leakage and anuria developed. She was intubated due to seizures and following sedation. Although in the course of time shock and bleeding stabilized, she continued to develop MODS and both pupils became progressively less reactive to light until nonreactive. CT brain imaging could not be performed. On day four, she died due to cardiac arrest.
No autopsies were performed on either of the patients. Written informed consent for publication of the disease histories was obtained from the direct relatives of both patients.
Case Discussion: Dengue and Curaçao
During the past decades dengue has been reported to occur in Curaçao. Until now fatal cases were never documented. However the 2010–2011 outbreak with 1,822 serologically confirmed cases was associated with four deaths (personal communication). Two of these patients had been previously diagnosed with SCD type HbSC and SCA. SCD is not uncommon in Curaçao, with a prevalence of approximately 0.25% [1]. Although chronic diseases such as SCD are considered to be a risk factor for development of severe dengue, few cases of children or adolescents have been reported [2].
Literature Review
Both in the Americas and Asia all four serotypes of DENV circulate with frequent reports of fatal dengue. Until now no cases of DENV infection in SCD patients have been described in Asia, probably due to the relatively low prevalence of SCD [3]. Furthermore reports describing patients with this combination of diseases are scarce, little-detailed, and restricted to a few fatal cases apart from the Cuban study concerning adults only (see Table 1) [4]–[10]. Bravo et al. reported 158 fatal cases during the 1981 DENV-2 epidemic in Cuba (72 children and 26 adults) [8]. Eight patients were suffering from sickle cell anemia, of which five presented with hemorrhages and three with shock. Half of them died within 24 hours after admission. The second article from Cuba describes a DENV-3 outbreak in 2001 [4]. Two fatal cases with HbSS and HbSC were reported. Both patients presented with fever. In one patient hemorrhage predominated, with plasma leakage leading to shock in the other case. Five or six days after admission, both patients died. In 1999 Ware et al. reported one fatal case of DHF in a SCA patient [6]. She presented with bone pain and fever, and she died four days after admission. Most cases described are HbSS patients. However none of the described cases suggests treatment options or case management, and interaction between both diseases is not described.
Presented Cases and Treatment Challenges
The clinical findings of the two cases described here are difficult to interpret because of the apparent complementary vascular endothelial damage in SCD, SCA, and severe dengue. As proposed in the model of dengue pathogenesis by Martina et al., DENV might replicate in selective endotheliocytes [11]. In SCD, endothelial dysfunction is known to occur [12]. There is no direct evidence from fatal dengue cases that dengue virus replicates in endothelial cells. Nonetheless, damage to endothelial cells as reflected by increased vascular permeability is central to the dengue vascular permeability syndrome (DHF/DSS). Vascular endothelial cells (VEC) play an important roll in inflammation and coagulation. By damaging the VEC either through infection of DENV or by sickling of erythrocytes, the permeability of the vascular endothelial layer can increase, which may induce plasma leakage, release of cytokines, and cause profound shock. Based on these findings, we hypothesize an essential role for endothelial cells to contribute to disease severity. The similarities between the cases are striking: shock, plasma leakage, hemorrhage, and MODS [2]. However plasma leakage predominated in case 1, whereas hemorrhage did in case 2. The onset of vaso-occlusion with SCD and SCA is often triggered by inflammation, as is the case in a DENV infection [12]. Severe bleeding seldom happens in children, but only in cases of profound shock, and no thrombotic complications are seen [13]. In treating dengue patients with underlying SCD or SCA, the treating physician is facing a dilemma. In SCD and SCA, it is preferred to maintain a low Ht to reduce the risk of vaso-occlusion. Treating physicians may be reluctant to perform blood transfusions in SCD patients because of concerns of excessive accumulation of iron, transfusion reactions, and alloimmunization. However severe anemia as a result of SCD or dengue may necessitate blood transfusion. The WHO reports an increase of Ht as a sign of plasma leakage with subsequently a decrease that may be due to hemorrhage. Both cases showed a continuing decrease of Ht, associated with hemorrhage with plasma leakage also predominating, suggesting Ht should not be used as a marker in patients with SCD or SCA. Iatrogenic interstitial fluid overload in patients with SCD, SCA, and severe dengue, due to preexisting vascular endothelial damage, is not just a theoretical hazard. Whether the clinical manifestations would just have been the result of secondary DENV infection only, despite SCD or SCA, remains a matter for debate. To further address this issue, we suggest that a case-control study should be performed to further elucidate the proposed association between severe dengue and SCD or SCA.
This report is based on two fatal cases of severe dengue with underlying SCD/SCA in Curaçao during the 2010–2011 epidemic. Currently no guidelines exist on how to treat such patients. In populations with a high prevalence of SCD, SCA, and dengue activity, clinicians should be aware of the challenges in clinical management.
Supporting Information
Table S1.
Detailed laboratory data of both patients.
https://doi.org/10.1371/journal.pntd.0002203.s001
(DOC)
References
- 1.
Dijs FP (2004) Sickle cell disease and α-thalassemia in Curaçao: contributors to epidemiology, pathophysiology and supportive care [dissertation]. Willemstad.
- 2.
World Health Organization (2009) Dengue guidelines: diagnosis, treatment, prevention and control. New edition 2009. Geneva: World Health Organization. pp. 1–160.
- 3.
World Health Organization (January 2011) Sickle-cell disease and other haemoglobin disorders. Fact sheet N°308. Available: http://www.who.int/mediacentre/factsheets/fs308/en/index.html. Accessed 5 July 2013.
- 4. Limonta D, González D, Capó V, Torres G, Pérez AB, et al. (2009) Fatal severe dengue and cell death in sickle cell disease during the 2001–2002 Havana dengue epidemic. Int J Infect Dis 13: 77–78.
- 5. Andrianarisoa ACE, Rakotoson J, Randretsa M, Rakotondravelo S, Rakotoarimanana RD, et al. (2007) Madagascar: public health situation on the “Big Island" at the beginning of the 21st century. Med Trop (Mars) 67: 19–29.
- 6. Ware MA, Hambleton I, Ochaya I, Serjeant GR (1999) Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol 104: 93–96.
- 7. Teruel-López E (1991) Dengue. A review. Invest Clin 32: 201–217.
- 8. Bravo JR, Guzmán MG, Kouri GP (1987) Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 81: 816–820.
- 9. Gentilini M, Laroche V, Degremont A (1964) Aspects of parasitic and infectious tropical pathology in the Republic of Haiti. Bull Soc Pathol Exot Filiales 57: 565–570.
- 10. González D, Castro OE, Kourí G, Perez J, Martinez E, et al. (2005) Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001–2002. Int J Infect Dis 9: 280–285.
- 11. Martina BEE, Koraka P, Osterhaus ADME (2009) Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 22: 564–581.
- 12. Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376: 2018–2031.
- 13. Halstead SB (2007) Dengue. Lancet 370: 1644–1652.